Ollin Biosciences Reports Positive Phase 1b Results for OLN324 in Retinal Diseases

Ollin Biosciences has announced positive 20-week results from its Phase 1b JADE trial, evaluating OLN324 against Vabysmo in patients with diabetic macular edema (DME) and wet age-related macular degeneration.

The study showed that OLN324 delivered stronger and more durable anatomical improvements, including greater retinal drying and faster reduction in pigment epithelial detachments. Patients also experienced sustained vision gains that were numerically better than faricimab, with fewer retreatments required.

In DME, 93% of patients on OLN324 completed 12 weeks without retreatment, compared to 89% on faricimab. In wAMD, results were comparable but favoured OLN324 in vision improvement.

The therapy demonstrated a favourable safety profile, with no cases of intraocular inflammation reported.

These findings support advancing OLN324 into global Phase III trials later this year.

01-04-2026